A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Business description not available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 3.1B | 3.1B | 2.9B | 2.5B | 2.6B | 2.3B |
| Net Income | 359M | 359M | 190M | 191M | 420M | 430M |
| EPS | $1.61 | $1.61 | $0.85 | $0.84 | $1.81 | $1.81 |
| Free Cash Flow | 399M | 399M | 439M | 392M | 493M | 292M |
| ROIC | 22.9% | 15.5% | 8.8% | 7.3% | 16.1% | 16.8% |
| Gross Margin | 45.3% | 45.3% | 48.3% | 49.2% | 51.0% | 51.3% |
| Debt/Equity | 0.00 | 0.36 | 0.52 | 0.58 | 0.36 | 0.45 |
| Dividends/Share | $0.80 | $0.80 | $0.64 | $0.56 | $0.53 | $0.47 |
| Operating Income | 612M | 612M | 367M | 282M | 582M | 579M |
| Operating Margin | 19.6% | 19.6% | 12.8% | 11.2% | 22.8% | 24.7% |
| ROE | 15.5% | 15.5% | 8.6% | 8.9% | 17.0% | 20.0% |
| Shares Outstanding | 222M | 222M | 221M | 227M | 230M | 235M |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 2.3B | 2.6B | 2.5B | 2.9B | 3.1B | 3.1B |
| Gross Margin | 51.3% | 51.0% | 49.2% | 48.3% | 45.3% | 45.3% |
| R&D | -137M | -143M | -144M | -149M | -141M | -141M |
| SG&A | -509M | -561M | -615M | -767M | -671M | -671M |
| EBIT | 579M | 582M | 282M | 367M | 612M | 612M |
| Op. Margin | 24.7% | 22.8% | 11.2% | 12.8% | 19.6% | 19.6% |
| Net Income | 430M | 420M | 191M | 190M | 359M | 359M |
| Net Margin | 18.4% | 16.5% | 7.6% | 6.6% | 11.5% | 11.5% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | 16.8% | 16.1% | 7.3% | 8.8% | 15.5% | 22.9% |
| ROE | 20.0% | 17.0% | 8.9% | 8.6% | 15.5% | 15.5% |
| ROA | 10.4% | 9.6% | 4.3% | 4.1% | 7.0% | 7.0% |
| Cash Flow | ||||||
| Op. Cash Flow | 464M | 638M | 530M | 608M | 564M | 564M |
| Free Cash Flow | 292M | 493M | 392M | 439M | 399M | 399M |
| Owner Earnings | 464M | 638M | 530M | 608M | 564M | 564M |
| CapEx | 172M | 145M | 138M | 169M | 165M | 165M |
| Maint. CapEx | 0 | 0 | 0 | 0 | 0 | 0 |
| Growth CapEx | N/A | N/A | N/A | N/A | N/A | 165M |
| D&A | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx/OCF | 37.1% | 22.7% | 26.0% | 27.8% | 29.3% | 29.3% |
| Capital Allocation | ||||||
| Dividends Paid | 110M | 121M | 128M | 141M | 178M | 178M |
| Dividend Yield | 2.0% | 2.2% | 3.4% | 3.5% | 4.2% | 6.1% |
| Share Buybacks | 368M | 0 | 3.0M | 0 | 38M | 38M |
| Buyback Yield | 6.1% | 0.0% | 0.1% | 0.0% | 0.9% | 1.3% |
| Stock-Based Comp | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | 636M | 463M | 976M | 927M | 646M | -188M |
| Cash & Equiv. | 323M | 426M | 270M | 205M | 188M | 188M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.45 | 0.36 | 0.58 | 0.52 | 0.36 | 0.00 |
| Interest Coverage | 8.4 | 8.4 | 3.5 | 3.9 | 3.7 | 3.7 |
| Equity | 2.1B | 2.5B | 2.1B | 2.2B | 2.3B | 2.3B |
| Total Assets | 4.1B | 4.4B | 4.5B | 4.7B | 5.1B | 5.1B |
| Total Liabilities | 2.0B | 1.9B | 2.3B | 2.5B | 2.8B | 2.8B |
| Intangibles | 289M | 285M | 389M | 1.1B | 1.2B | 1.2B |
| Retained Earnings | 1.9B | 2.2B | 2.1B | 2.2B | 2.4B | 2.4B |
| Working Capital | 894M | 1.1B | 922M | 761M | 285M | 285M |
| Current Assets | 1.9B | 2.1B | 2.0B | 2.1B | 2.3B | 2.3B |
| Current Liabilities | 1.0B | 1.0B | 1.1B | 1.3B | 2.0B | 2.0B |
| Per Share Data | ||||||
| EPS | 1.81 | 1.81 | 0.84 | 0.85 | 1.61 | 1.61 |
| Owner EPS | 1.97 | 2.77 | 2.33 | 2.75 | 2.55 | 2.55 |
| Book Value | 9.12 | 10.71 | 9.45 | 9.95 | 10.42 | 10.42 |
| Cash Flow/Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.62 |
| Dividends/Share | 0.47 | 0.53 | 0.56 | 0.64 | 0.80 | 0.80 |
| Shares Out. | 235.5M | 230.4M | 227.4M | 220.9M | 221.6M | 221.6M |
| Valuation | ||||||
| P/E Ratio | 14.2 | 12.3 | 17.9 | 21.0 | 12.3 | 8.2 |
| P/FCF | 20.8 | 10.4 | 8.7 | 9.0 | 11.0 | 7.3 |
| EV/EBIT | 11.6 | 9.6 | 15.6 | 13.3 | 8.2 | 4.5 |
| Price/Book | 2.8 | 2.1 | 1.6 | 1.8 | 1.9 | 1.3 |
| Price/Sales | 2.6 | 2.0 | 1.4 | 1.4 | 1.4 | 0.9 |
| FCF Yield | 4.8% | 9.6% | 11.5% | 11.1% | 9.1% | 13.6% |
| Market Cap | 6.1B | 5.1B | 3.4B | 4.0B | 4.4B | 2.9B |
| Avg. Price | 22.99 | 24.07 | 16.78 | 18.50 | 19.26 | 13.22 |
| Year-End Price | 25.80 | 22.20 | 15.04 | 17.89 | 19.82 | 13.22 |
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY passes 4 of 9 quality checks, suggesting mixed fundamentals.
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY trades at 8.2x trailing earnings, compared to its 15-year median P/E of 14.2x, suggesting it is currently Cheap relative to its historical range. On a free-cash-flow basis, the stock trades at 7.3x vs a median of 10.4x. The company's 5-year average ROIC is 12.9% with a gross margin of 49.0%. Total shareholder yield (dividends + buybacks) is 7.4%. At current prices, the estimated annualized return to fair value is +8.1%.
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY (HIK-L) has a current P/E ratio of 8.2, compared to its historical median P/E of 14.2. The stock is currently considered Cheap based on its historical valuation range.
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY (HIK-L) has a 5-year average return on invested capital (ROIC) of 12.9%. This indicates solid capital allocation.
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY (HIK-L) has a market capitalization of $2.9B. It is classified as a mid-cap stock.
Yes, HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY (HIK-L) pays a dividend with a trailing twelve-month yield of 6.08%. The company also returns capital through share buybacks, with a buyback yield of 1.30%.
Based on historical P/E analysis, HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY (HIK-L) appears cheap. The current P/E of 8.2 is 42% below its historical median of 14.2. The estimated fair value CAGR (P/E method) is -7.2%.
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY (HIK-L) reported annual revenue of $3.1 billion in its most recent fiscal year, based on SEC EDGAR filings.
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY (HIK-L) has a net profit margin of 11.5%. This is a healthy margin.
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY (HIK-L) generated $399 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY (HIK-L) has a debt-to-equity ratio of 0.36. This indicates a conservatively financed balance sheet.
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY (HIK-L) reported earnings per share (EPS) of $1.61 in its most recent fiscal year.
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY (HIK-L) has a return on equity (ROE) of 15.5%. This indicates the company generates strong returns for shareholders.
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY (HIK-L) has a 5-year average gross margin of 49.0%. This indicates decent pricing power.
The Ledger Terminal provides 5 years of financial data for HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY (HIK-L), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY (HIK-L) has a book value per share of $10.42, based on its most recent annual SEC filing.
No recent press releases.